Skip to main content
Year archive

ALTERITY THERAPEUTICS LIMITED — 2017 filings

All 32 regulatory filings released by ALTERITY THERAPEUTICS LIMITED (ATH) in 2017, sourced directly from the official regulator.

32 Filings
2017 Period
2017 filings (32)
Filing Released Lang
Change of Director's Interest Notice 2 pages 544.1KB
Director's Dealing
2017-12-21 English
Change of Director's Interest Notice 2 pages 542.9KB
Director's Dealing
2017-12-21 English
Change of Director's Interest Notice 2 pages 542.5KB
Director's Dealing
2017-12-21 English
Change of Director's Interest Notice 2 pages 542.3KB
Director's Dealing
2017-12-21 English
Change of Director's Interest Notice 2 pages 542.1KB
Director's Dealing
2017-12-21 English
Prana receives $3 million R&D Tax Incentive Refund 1
Capital/Financing Update
2017-12-18 English
Appendix 3B 9 pages 827.6KB
Capital/Financing Update
2017-12-18 English
AGM 2017 Presentation 8 pages 1.0MB
Investor Presentation
2017-11-16 English
2017 AGM Results of Meeting 1 page 88.6KB
Declaration of Voting Results & Voting Rights Announcements
2017-11-16 English
Prana AGM Investor Conference Call 2 pages 928.9KB
AGM Information
2017-11-09 English
Prospectus Supplement 47 pages 159.6KB
Capital/Financing Update
2017-11-08 English
Form 6-K 11 pages 74.5KB
Capital/Financing Update
2017-11-08 English
Appendix 4C - quarterly 5 pages 712.5KB
Interim / Quarterly Report
2017-10-29 English
Notice of Meeting/ Proxy Form 24 pages 13.3MB
Regulatory Filings
2017-10-12 English
Form F-3 46 pages 265.9KB
Capital/Financing Update
2017-10-10 English
Change of Address 2 pages 631.7KB
Regulatory Filings
2017-09-24 English
Annual Report filed on Form 20-F with SEC 1 page 61
Report Publication Announcement
2017-09-05 English
Form 20-F 143 pages 861.9KB
Annual Report
2017-08-31 English
Appendix 4E and Annual Report 107 pages 2.2MB
Annual Report
2017-08-30 English
Appendix 4G 11 pages 268.7KB
Governance Information
2017-08-30 English
Appendix 4C - quarterly 5 pages 712.2KB
Interim / Quarterly Report
2017-07-26 English
Prana commences research collaboration with Takeda 2 pages 631.6KB
Regulatory Filings
2017-07-17 English
PBT434 Lowers Alpha-Synuclein and Prevents Neurodegeneration 3 pages 701.3KB
Regulatory Filings
2017-07-02 English
Change of address 2 pages 370.6KB
Regulatory Filings
2017-06-25 English
Appendix 3B 9 pages 831.4KB
Capital/Financing Update
2017-06-06 English
David Stamler appointed as CMO to lead Clinical Development 2 pages 637.3KB
Board/Management Information
2017-06-04 English
Appendix 4C - quarterly 5 pages 55.2KB
Interim / Quarterly Report
2017-04-26 English
PBT434 presented at 13th International AD/PD Conference 2 pages 375.9KB
Investor Presentation
2017-03-29 English
Half Year Accounts 22 pages 290.9KB
Regulatory Filings
2017-02-23 English
Form 6-K 20 pages 230.0KB
Interim / Quarterly Report
2017-02-23 English
Appendix 4C - quarterly 5 pages 267.8KB
Interim / Quarterly Report
2017-01-29 English
Response to ASX Price Query 5 pages 485.3KB
Regulatory Filings
2017-01-08 English